A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma CANDOR Study of Carfilzomib ANd Daratumumab fOr Relapsed Myeloma
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms CANDOR
- Sponsors Amgen
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.
- 20 Jun 2017 Planned End Date changed from 25 Jun 2022 to 23 Jun 2022.
- 20 Jun 2017 Planned primary completion date changed from 9 Sep 2019 to 7 Sep 2019.